Research

Mixed

Combining tirzepatide with low-energy ketogenic therapy (LEKT) produces significantly greater reductions in hepatic steatosis and liver stiffness than combining tirzepatide with a low-calorie diet (LCD), independent of total body weight loss.

If you have MASLD and are using tirzepatide, adding a structured low-energy ketogenic diet (under 30g carbs, ~1200 kcal) for 12 weeks may reduce liver fat and stiffness more effectively than a standard low-calorie diet, even if your total weight loss is similar. This requires strict adherence and monitoring, ideally under medical supervision, to ensure safety and efficacy.

ModerateSupportsMEDIUM confidence
Both groups showed significant reductions in body weight... with no significant intergroup difference... CAP and LSM improved significantly in both groups, but reductions were greater in the TZP + LEKT group (CAP −12.5%, p < 0.001; LSM −22.7%, p < 0.001) versus LCD (CAP −6.7%, p = 0.014; LSM −9.2%, p = 0.022).
Luigi Schiavo et al. · Nutrients · 2025

Why this rating

The study is a prospective, non-randomized pilot with a small sample size (n=60) and short duration (12 weeks), limiting generalizability and causal inference.

Source

Beyond Weight Loss: Comparative Effects of Tirzepatide Plus Low-Energy Ketogenic Versus Low-Calorie Diet on Hepatic Steatosis and Stiffness in MASLD

Luigi Schiavo et al. · Nutrients · 2025

DOI 10.3390/nu17152409

cohort · n=60Cited 5×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →